Medulloblastoma is a malignant embryonic brain tumor arising in the posterior fossa and typically occurring in pediatric patients. Current multimodal treatment regimes have significantly improved the survival rates; however, a marked heterogeneity in therapy response is observed, and one third of all patients die within 5 years after diagnosis. Large-scale genetic and transcriptome analysis revealed four medulloblastoma subgroups (WNT, SHH, Group 3, and Group 4) associated with different demographic parameters, tumor manifestation, and clinical behavior. Future treatment protocols will integrate molecular classification schemes to evaluate subgroup-specific intensification or de-escalation of adjuvant therapies aimed to increase tumor control and reduce iatrogenic induced morbidity. Furthermore, the identification of genetic drivers allows assessing target therapies in order to increase the chemotherapeutic armamentarium. This review highlights the biology behind the current classification system and elucidates relevant aspects of the disease influencing forthcoming clinical trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11910-016-0644-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pediatric Brain Tumors in Western Kenya: Patient Outcomes and Healthcare Providers' Perspectives.
Pediatr Blood Cancer
January 2025
Academic Model Providing Access to Healthcare (AMPATH), Eldoret, Kenya.
Article Synopsis
- Pediatric brain tumors in low- and middle-income countries, particularly Western Kenya, are less studied than other pediatric cancers, and effective care relies on collaboration among multiple medical departments.
- The study found that, between 2015 and 2022, 79 children were diagnosed with brain tumors, primarily medulloblastoma, with a low 2-year event-free survival rate of 13% and a significant treatment abandonment rate of 46%.
- Improvements in multidisciplinary care were noted from 2020 to 2022, influenced by factors such as resources, knowledge, and relationships among healthcare workers; addressing these barriers is essential for enhancing patient outcomes.
Development of a simple prediction model for tracheostomy requirement after surgical resection of medulloblastoma in children.
BMC Res Notes
January 2025
Shiraz Neuroscience Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Objective: Postoperative tracheostomy is a significant complication following medulloblastoma (MB) resection. This study aimed to develop a predictive model for postoperative tracheostomy requirement in children undergoing MB surgical resection. This model was derived as a side product of a larger research project analyzing surgical outcomes in pediatric MB patients.
View Article and Find Full Text PDFIn-depth inference of transcriptional regulatory networks reveals NPM1 as a therapeutic ribosomal regulator in MYC-amplified medulloblastoma.
NPJ Precis Oncol
January 2025
Division of Neonatology and Center for Newborn Care, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Medulloblastoma (MB) is an aggressive pediatric brain tumor with distinct molecular heterogeneity. Identifying subtype-specific signatures within Group 3 and Group 4 remains challenging due to shared cytogenetic alterations and limitations of conventional differential gene expression analysis. To uncover the underlying molecular signatures and hidden regulators, we used the Cavalli transcriptomic profile of 470 Group 3 and Group 4 MB patients to reconstruct subtype-specific regulatory networks.
View Article and Find Full Text PDFTemporal Trends of Subsequent CNS Malignancies Among Survivors of Childhood Cancer.
J Natl Cancer Inst
January 2025
Division of Pediatric Hematology & Oncology, University of Minnesota, Minneapolis, MN, USA.
Purpose: It is not known whether temporal changes in childhood cancer therapy have reduced risk of subsequent malignant neoplasms (SMNs) of the central nervous system (CNS), a frequently fatal late effect of cancer therapy.
Methods: Five-year survivors of primary childhood cancers diagnosed between 1970-1999 in the Childhood Cancer Survivor Study with a subsequent CNS SMN were identified. Cumulative incidence rates and standardized incidence ratios (SIR) were compared among survivors diagnosed between 1970-1979 (N = 6223), 1980-1989 (N = 9680), and 1990-1999 (N = 8999).
Impact of Pediatric Posterior Fossa Tumor Treatments on Working Memory Tracts Using Resting-State fMRI and Tractography.
J Neuroimaging
January 2025
Toulouse NeuroImaging Center (ToNIC), INSERM, University of Toulouse Paul Sabatier, Toulouse, France.
Background And Purpose: Working memory, a primary cognitive domain, is often impaired in pediatric brain tumor survivors, affecting their attention and processing speed. This study investigated the long-term effects of treatments, including surgery, radiotherapy (RT), and chemotherapy (CT), on working memory tracts in children with posterior fossa tumors (PFTs) using resting-state functional MRI (rs-fMRI) and diffusion MRI tractography.
Methods: This study included 16 medulloblastoma (MB) survivors treated with postoperative RT and CT, 14 pilocytic astrocytoma (PA) survivors treated with surgery alone, and 16 healthy controls from the Imaging Memory after Pediatric Cancer in children, adolescents, and young adults study (NCT04324450).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!